Parabilis Medicines, Inc. Common Stock (PBLS) - Total Assets
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) holds total assets worth $384.17 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PBLS stock price and chart for real-time trading data and today's change.
Parabilis Medicines, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see PBLS operating cash flow for how efficiently the company converts equity into cash flow.
Parabilis Medicines, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Parabilis Medicines, Inc. Common Stock's total assets of $384.17 Million consist of 36.3% current assets and 63.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PBLS working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Parabilis Medicines, Inc. Common Stock's current assets represent 36.3% of total assets in 2025, a decrease from 61.8% in 2024.
- Cash Position: Cash and equivalents constituted 34.3% of total assets in 2025, up from 31.7% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Parabilis Medicines, Inc. Common Stock Competitors by Total Assets
Key competitors of Parabilis Medicines, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
iNtRON Biotechnology Inc
KQ:048530
|
Korea | ₩78.70 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
Parabilis Medicines, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.12 | - | - |
| Quick Ratio | 6.12 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $277.83 Million | - | - |
Parabilis Medicines, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Parabilis Medicines, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 52.94 |
| Asset Growth Rate (YoY) | -45.9% |
| Total Assets | $80.82 Million |
| Market Capitalization | $4.28 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Parabilis Medicines, Inc. Common Stock's assets at a significant premium (52.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Parabilis Medicines, Inc. Common Stock's assets decreased by 45.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Parabilis Medicines, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $80.82 Million | -45.85% |
| 2024-12-31 | $149.25 Million | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more